Tff Pharmaceuticals Stock Today
| TFFP Stock | USD 2.21 0.04 1.84% |
Performance5 of 100
| Odds Of DistressLess than 18
|
Tff Pharmaceuticals is selling at 2.21 as of the 13th of September 2024; that is 1.84 percent increase since the beginning of the trading day. The stock's last reported lowest price was 2.02. Tff Pharmaceuticals has less than a 18 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Tff Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of August 2024 and ending today, the 13th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of October 2019 | Category Healthcare | Classification Health Care |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing technology platform in the United States and Australia. The company was incorporated in 2018 and is based in Austin, Texas. The company has 3.47 M outstanding shares of which 140.27 K shares are at this time shorted by private and institutional investors with about 5.18 trading days to cover. More on Tff Pharmaceuticals
Moving against Tff Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Tff Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Biotech (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Biotech, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTff Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Tff Pharmaceuticals' financial leverage. It provides some insight into what part of Tff Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Tff Pharmaceuticals (TFFP) is traded on NASDAQ Exchange in USA. It is located in 1751 River Run, Fort Worth, TX, United States, 76107 and employs 19 people. Tff Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 7.66 M. Tff Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 3.47 M outstanding shares of which 140.27 K shares are at this time shorted by private and institutional investors with about 5.18 trading days to cover.
Tff Pharmaceuticals currently holds about 13.15 M in cash with (16.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51.
Check Tff Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationTff Pharmaceuticals has 4.2 % of its outstanding shares held by insiders and 22.48 % owned by institutional holders.
Check Tff Ownership Details
Tff Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Org Partners Llc | 2024-03-30 | 740 | |
| Tower Research Capital Llc | 2024-03-31 | 502 | |
| Newbridge Financial Services Group, Inc. | 2024-03-31 | 434 | |
| Royal Bank Of Canada | 2024-06-30 | 156 | |
| Raleigh Capital Management Inc. | 2024-06-30 | 91.0 | |
| Wells Fargo & Co | 2024-06-30 | 61.0 | |
| Hm Payson & Co | 2024-06-30 | 60.0 | |
| Advisor Group Holdings, Inc. | 2024-03-31 | 40.0 | |
| Morgan Stanley - Brokerage Accounts | 2024-03-31 | 32.0 | |
| Carlson Capital Lp | 2024-06-30 | 293.5 K | |
| Armistice Capital, Llc | 2024-06-30 | 185.7 K |
Tff Pharmaceuticals Historical Income Statement
Tff Stock Against Markets
Tff Pharmaceuticals Corporate Management
| Harlan Weisman | Interim Chairman | Profile | |
| Zamaneh MD | Chief Officer | Profile | |
| Kirk Coleman | Treasurer CFO | Profile | |
| Paul Manley | Head Affairs | Profile | |
| Anthony Hickey | Chief Officer | Profile | |
| Christopher Cano | COO Devel | Profile | |
| Dale Christensen | Head Devel | Profile |
Additional Tools for Tff Stock Analysis
When running Tff Pharmaceuticals' price analysis, check to measure Tff Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tff Pharmaceuticals is operating at the current time. Most of Tff Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tff Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tff Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tff Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.